No Data
Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD) and Jasper Therapeutics (JSPR)
Capital One Financial Maintains Jasper Therapeutics(JSPR.US) With Buy Rating, Maintains Target Price $55
Capital One Financial analyst Tim Chiang maintains $Jasper Therapeutics(JSPR.US)$ with a buy rating, and maintains the target price at $55.According to TipRanks data, the analyst has a success rate
TD Cowen Maintains Jasper Therapeutics(JSPR.US) With Buy Rating
TD Cowen analyst Yaron Werber maintains $Jasper Therapeutics(JSPR.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 58.6% and a total average return of 15.2% over
TD Cowen Remains a Buy on Jasper Therapeutics (JSPR)
Express News | Jasper Therapeutics Shares Rise 6.6% Premarket After Btig Initiates Coverage With Buy Rating
Express News | Jasper Therapeutics Inc : Btig Initiates Coverage With Buy Rating and $90 Price Target